Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |

Journal website http://www.jocmr.org |

Original Article

Volume 11, Number 9, September 2019, pages 642-650

**Assessment of Gap Junction Protein Beta-2 rs3751385 Gene Polymorphism in Psoriasis Vulgaris**

Tables

Patients | Controls | P value | |
---|---|---|---|

Hardy-Weinberg equilibrium. Controls: χ^{2} = 0.341, df = 1, P = 0.559. Patients: χ^{2} = 0.086, df = 1, P = 0.769. | |||

No. | 173 | 171 | |

Age (years; mean ± SD) | 48.97 ± 16.06 | 48.56 ± 15.96 | 0.810 |

Gender | 0.884 | ||

Male | 111 (64.2%) | 111 (64.9%) | |

Female | 62 (35.8%) | 60 (35.1%) | |

Age onset | |||

Early | 108 (62.4%) | - | |

Late | 65 (37.6%) | - |

Controls* | Patients* | OR^{†} | 95% CI | P value | |
---|---|---|---|---|---|

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with psoriasis vulgaris and healthy controls: 1) χ^{2} = 3.033, df = 2, P = 0.219; χ^{2} = 2.913, df = 1, P = 0.088; χ^{2} = 2.919, df = 1, P = 0.088 among the entire cohort; 2) χ^{2} = 1.164, df = 2, P = 0.559; χ^{2} =1 .108, df = 1, P = 0.293; χ^{2} = 0.883, df = 1, P = 0.347 among males; 3) χ^{2} = 2.630, df = 2, P = 0.269; χ^{2} = 2.109, df = 1, P = 0.146; χ^{2} = 2.455, df = 1, P = 0.117 among females. *Data are number of subjects and percentage (%). ^{†}Adjusted for age and gender. OR: odds ratio; CI: confidence interval. | |||||

Total | |||||

Genotype | |||||

C/C | 111 (64.9%) | 127 (73.4%) | Ref. | ||

C/T | 55 (32.2%) | 43 (24.9%) | 0.68 | 0.42 - 1.10 | 0.113 |

T/T | 5 (2.9%) | 3 (1.7%) | 0.51 | 0.12 - 2.21 | 0.372 |

Recessive model | |||||

C/C | 111 (64.9%) | 127 (73.4%) | Ref. | ||

C/T or T/T | 60 (35.1%) | 46 (26.6%) | 0.67 | 0.42 - 1.06 | 0.087 |

Allele contrast | |||||

C | 277 (81.0%) | 297 (85.8%) | Ref. | ||

T | 65 (19.0%) | 49 (14.2%) | 0.70 | 0.47 - 1.05 | 0.086 |

Males | |||||

Genotype | |||||

C/C | 77 (69.4%) | 84 (75.7%) | Ref. | ||

C/T | 32 (28.8%) | 25 (22.5%) | 0.72 | 0.39 - 1.32 | 0.283 |

T/T | 2 (1.8%) | 2 (1.8%) | 0.92 | 0.13 - 6.69 | 0.931 |

Recessive model | |||||

C/C | 77 (69.4%) | 84 (75.7%) | Ref. | ||

C/T or T/T | 34 (30.6%) | 27 (24.3%) | 0.73 | 0.40 - 1.32 | 0.293 |

Allele contrast | |||||

C | 186 (83.8%) | 193 (86.9%) | Ref. | ||

T | 36 (16.2%) | 29 (13.1%) | 0.78 | 0.46 - 1.32 | 0.349 |

Females | |||||

Genotype | |||||

C/C | 34 (56.7%) | 43 (69.4%) | Ref. | ||

C/T | 23 (38.3%) | 18 (29.0%) | 0.62 | 0.29 - 1.34 | 0.227 |

T/T | 3 (5.0%) | 1 (1.6%) | 0.26 | 0.03 - 2.64 | 0.256 |

Recessive model | |||||

C/C | 34 (56.7%) | 43 (69.4%) | Ref. | ||

C/T or T/T | 26 (43.3%) | 19 (30.6%) | 0.58 | 0.28 - 1.22 | 0.153 |

Allele contrast | |||||

C | 91 (75.8%) | 104 (83.9%) | Ref. | ||

T | 29 (24.2%) | 20 (16.1%) | 0.61 | 0.32 - 1.15 | 0.123 |

Controls* | Early onset* | OR^{†} | 95% CI | P value | |
---|---|---|---|---|---|

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with early onset psoriasis and healthy controls: 1) χ^{2} = 2.047, df = 2, P = 0.359; χ^{2} = 1.227, df = 1, P = 0.268; χ^{2} = 1.619, df = 1, P = 0.203 among the entire cohort; 2) χ^{2} = 0.047, df = 2, P = 0.977; χ^{2} = 0.000, df = 1, P = 0.991; χ^{2} = 0.004, df = 1, P = 0.951 among males; 3) χ^{2} = 4.190, df = 2, P = 0.123; χ^{2} = 3.264, df = 1, P = 0.071; χ^{2} = 3.858, df = 1, P = 0.049 among females. *Data are number of subjects and percentage (%). ^{†}Adjusted for age and gender. ^{‡}Statistically significant P values. OR: odds ratio; CI: confidence interval. | |||||

Total | |||||

Genotype | |||||

C/C | 111 (64.9%) | 77 (71.3%) | Ref.^{†} | ||

C/T | 55 (32.2%) | 30 (27.8%) | 0.76 | 0.44 - 1.32 | 0.331 |

T/T | 5 (2.9%) | 1 (0.9%) | 0.34 | 0.04 - 3.11 | 0.336 |

Recessive model | |||||

C/C | 111 (64.9%) | 77 (71.3%) | Ref. | ||

C/T or T/T | 60 (35.1%) | 31 (28.7%) | 0.73 | 0.42 - 1.26 | 0.254 |

Allele contrast | |||||

C | 277 (81.0%) | 184 (85.2%) | Ref. | ||

T | 65 (19.0%) | 32 (14.8%) | 0.74 | 0.46 - 1.19 | 0.216 |

Males | |||||

Genotype | |||||

C/C | 77 (69.4%) | 50 (69.4%) | Ref. | ||

C/T | 32 (28.8%) | 21 (29.2%) | 1.04 | 0.53 - 2.05 | 0.914 |

T/T | 2 (1.8%) | 1 (1.4%) | 0.95 | 0.08 - 12.07 | 0.968 |

Recessive model | |||||

C/C | 77 (69.4%) | 50 (69.4%) | Ref. | ||

C/T or T/T | 34 (30.6%) | 22 (30.6%) | 1.03 | 0.53 - 2.02 | 0.923 |

Allele contrast | |||||

C | 186 (83.8%) | 121 (84.0%) | Ref. | ||

T | 36 (16.2%) | 23 (16.0%) | 1.02 | 0.57 - 1.85 | 0.940 |

Females | |||||

Genotype | |||||

C/C | 34 (56.7%) | 27 (75.0%) | Ref. | ||

C/T | 23 (38.3%) | 9 (25.0%) | 0.42 | 0.16 - 1.09 | 0.076 |

T/T | 3 (5.0%) | 0 (0.0%) | - | - | - |

Recessive model | |||||

C/C | 34 (56.7%) | 27 (75.0%) | Ref. | ||

C/T or T/T | 26 (43.3%) | 9 (25.0%) | 0.44 | 0.18 - 1.08 | 0.074 |

Allele contrast | |||||

C | 91 (75.8%) | 63 (87.5%) | Ref. | ||

T | 29 (24.2%) | 9 (12.5%) | 0.41 | 0.18 - 0.95 | 0.038^{‡} |

Controls* | Late onset* | OR^{†} | 95% CI | P value | |
---|---|---|---|---|---|

Statistical significance for differences in genotype, G-containing genotype and allelic frequencies between patients with late onset psoriasis and healthy controls: 1) χ^{2} = 3.418, df = 2, P = 0.181; χ^{2} = 3.134, df = 1, P = 0.077; χ^{2} = 2.307, df = 1, P = 0.129 among the entire cohort; 2) χ^{2} = 5.469, df = 2, P = 0.065; χ^{2} = 4.758, df = 1, P = 0.029; χ^{2} = 3.483, df = 1, P = 0.062 among males; 3) χ^{2} = 0.193, df = 2, P = 0.908; χ^{2} = 0.177, df = 1, P = 0.674; χ^{2} = 0.185, df = 1, P = 0.668 among females. *Data are number of subjects and percentage (%). ^{†}Adjusted for age and gender. ^{‡}Statistically significant P values. OR: odds ratio; CI: confidence interval. | |||||

Total | |||||

Genotype | |||||

C/C | 111 (64.9%) | 50 (76.9%) | Ref.^{†} | ||

C/T | 55 (32.2%) | 13 (20.0%) | 0.56 | 0.26 - 1.19 | 0.134 |

T/T | 5 (2.9%) | 2 (3.1%) | 0.64 | 0.10 - 3.96 | 0.632 |

Recessive model | |||||

C/C | 111 (64.9%) | 50 (76.9%) | Ref. | ||

C/T or T/T | 60 (35.1%) | 15 (23.1%) | 0.57 | 0.27 - 1.17 | 0.127 |

Allele contrast | |||||

C | 277 (81.0%) | 113 (86.9%) | Ref. | ||

T | 65 (19.0%) | 17 (13.1%) | 0.63 | 0.33 - 1.19 | 0.155 |

Males | |||||

Genotype | |||||

C/C | 77 (69.4%) | 34 (87.2%) | Ref. | ||

C/T | 32 (28.8%) | 4 (10.3%) | 0.22 | 0.07 - 0.77 | 0.017^{‡} |

T/T | 2 (1.8%) | 1 (2.6%) | 0.43 | 0.03 - 6.71 | 0.547 |

Recessive model | |||||

C/C | 77 (69.4%) | 34 (87.2%) | Ref. | ||

C/T or T/T | 34 (30.6%) | 5 (12.8%) | 0.24 | 0.08 - 0.77 | 0.016^{‡} |

Allele contrast | |||||

C | 186 (83.8%) | 72 (92.3%) | Ref. | ||

T | 36 (16.2%) | 6 (7.7%) | 0.31 | 0.12 - 0.85 | 0.023^{‡} |

Females | |||||

Genotype | |||||

C/C | 34 (56.7%) | 16 (61.5%) | Ref. | ||

C/T | 23 (38.3%) | 9 (34.6%) | 1.37 | 0.45 - 4.19 | 0.583 |

T/T | 3 (5.0%) | 1 (3.8%) | 0.99 | 0.09 - 11.68 | 0.999 |

Recessive model | |||||

C/C | 34 (56.7%) | 16 (61.5%) | Ref. | ||

C/T or T/T | 26 (43.3%) | 10 (38.5%) | 1.32 | 0.45 - 3.86 | 0.618 |

Allele contrast | |||||

C | 91 (75.8%) | 41 (78.8%) | Ref. | ||

T | 29 (24.2%) | 11 (21.1%) | 1.18 | 0.49 - 2.82 | 0.668 |